These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 20606192)

  • 21. The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin.
    Koren MJ; Smith DG; Hunninghake DB; Davidson MH; McKenney JM; Weiss SR; Schrott HG; Henley RW; Tresh P; McLain RW; Bakker-Arkema RG; Black DM
    Pharmacoeconomics; 1998 Jul; 14(1):59-70. PubMed ID: 10182195
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Utilization of Generic Cardiovascular Drugs in Medicare's Part D Program.
    Ma I; Tisdale RL; Vail D; Heidenreich PA; Sandhu AT
    Circ Cardiovasc Qual Outcomes; 2021 Dec; 14(12):e007559. PubMed ID: 34879702
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Generic Competition on Atorvastatin Prescribing and Patients' Out-of-Pocket Spending.
    Luo J; Seeger JD; Donneyong M; Gagne JJ; Avorn J; Kesselheim AS
    JAMA Intern Med; 2016 Sep; 176(9):1317-23. PubMed ID: 27367749
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does knowledge of medication prices predict physicians' support for cost effective prescribing policies.
    Polinski JM; Maclure M; Marshall B; Cassels A; Agnew-Blais J; Patrick AR; Schneeweiss S
    Can J Clin Pharmacol; 2008; 15(2):e286-94. PubMed ID: 18641423
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
    Mullins CD; Rattinger GB; Kuznik A; Koren MJ
    Clin Ther; 2008; 30 Pt 2():2204-16. PubMed ID: 19281915
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term Medicaid excess payments from alleged price manipulation of generic lorazepam.
    Bian B; Gorevski E; Kelton CM; Guo JJ; Martin Boone JE
    J Manag Care Pharm; 2012 Sep; 18(7):506-15. PubMed ID: 22971204
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of Medicaid prescription copayments on use of antipsychotics and other medications in patients with schizophrenia.
    Doshi JA; Li P; Desai S; Marcus SC
    J Med Econ; 2017 Dec; 20(12):1252-1260. PubMed ID: 28792299
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins.
    Tran YB; Frial T; Miller PS
    Can J Clin Pharmacol; 2007; 14(2):e205-14. PubMed ID: 17556788
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Moving from A to Z: successful implementation of a statin switch program by a large physician group.
    Sy FZ; Choe HM; Kennedy DM; Standiford CJ; Parsons DM; Bruhnsen KD; Stevenson JG; Bernstein SJ
    Am J Manag Care; 2009 Apr; 15(4):233-40. PubMed ID: 19355796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin.
    Lindgren P; Graff J; Olsson AG; Pedersen TJ; Jönsson B;
    Eur Heart J; 2007 Jun; 28(12):1448-53. PubMed ID: 17371782
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Medication costs as a primary cause of nonadherence in the elderly.
    Lynch T
    Consult Pharm; 2006 Feb; 21(2):143-6. PubMed ID: 16524358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differences in the cost of antidepressants across state Medicaid programs.
    Kelton CM; Rebelein RP; Heaton PC; Ferrand Y; Guo JJ
    J Ment Health Policy Econ; 2008 Mar; 11(1):33-47. PubMed ID: 18424875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective.
    Costa-Scharplatz M; Ramanathan K; Frial T; Beamer B; Gandhi S
    Clin Ther; 2008 Jul; 30(7):1345-57. PubMed ID: 18691996
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Pfizer: TLV decision about antilipemic agents is founded on wrong basis].
    Brun J; Ohlsson-Onerud A; Sörensen N
    Lakartidningen; 2009 Apr 22-28; 106(17):1193-4; discussion 1194. PubMed ID: 19530431
    [No Abstract]   [Full Text] [Related]  

  • 35. Impact of out-of-pocket expenses on discontinuation of statin therapy: a cohort study in Finland.
    Helin-Salmivaara A; Korhonen MJ; Alanen T; Huupponen R
    J Clin Pharm Ther; 2012 Feb; 37(1):58-64. PubMed ID: 21410736
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of Variation in State Regulation of Generic Drug and Interchangeable Biologic Substitutions.
    Sacks CA; Van de Wiele VL; Fulchino LA; Patel L; Kesselheim AS; Sarpatwari A
    JAMA Intern Med; 2021 Jan; 181(1):16-22. PubMed ID: 32865564
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular and economic outcomes after initiation of lipid-lowering therapy with atorvastatin vs simvastatin in an employed population.
    Simpson RJ; Signorovitch J; Birnbaum H; Ivanova J; Connolly C; Kidolezi Y; Kuznik A
    Mayo Clin Proc; 2009 Dec; 84(12):1065-72. PubMed ID: 19955243
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patent cliff. Billions to be saved--starting now. Lipitor led the way, and other blockbusters are following.
    Manag Care; 2011 Nov; 20(11):65. PubMed ID: 22175110
    [No Abstract]   [Full Text] [Related]  

  • 39. Economic impacts attributable to the early clinical benefit of atorvastatin therapy--a US managed care perspective.
    Straka RJ; Mamdani M; Damen J; Kuntze CE; Liu LZ; Botteman MF; Koren MJ
    Curr Med Res Opin; 2007 Jul; 23(7):1517-29. PubMed ID: 17535539
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potential savings from generic prescribing and generic substitution in South Africa.
    Karim SS; Pillai G; Ziqubu-Page TT; Cassimjee MH; Morar MS
    Health Policy Plan; 1996 Jun; 11(2):198-205. PubMed ID: 10158460
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.